Daily Recap - WEDNESDAY
Join panelists Drs. Janet Pope, Richard Conway, Meral El Ramahi and Jack Cush recap the best presentations presented on day four of the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →What's hot
View all perspectives
What's Hot
EXXELERATE Study: Do High RF Titers Impact Response to TNF Inhibitors?
Dr. Jonathan Kay discusses abstract 2148 with Dr. Josef Smolen at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Bimekizumab in Active AS: 5 Year Study
Dr. Atul Deodhar reporting on abstract 0519 from the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Cannabinoid Receptor in RA Patients
Dr. Arthur Kavanaugh discusses abstract 0025 at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Treatments in SpA
Dr. Rachel Tate and Dr. Catherine Blakewell discuss treatment options patients in spondyloarthritis at the 2023 ACR Convergence meeting in San Diego, CA. Abstracts discussed include 0520, 0530, 0521 and 0529.
Watch video →
PR3+ in Lupus Nephritis
Dr. Jack Cush discusses abstract 2427 presented at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Simulated Trials to Counter ORAL Survelliance
Dr. Jack Cush and Dr. Janet Pope at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Difficult to Treat axSpA
Dr. Peter Nash reports on abstracts 0514 and 0538 from the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Window of Opportunity in PsA
Dr. Peter Nash discusses a study that looks at the window of opportunity for treatment of PsA at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
TMP SMX Prophylaxis in GPA
Dr. Jack Cush and Dr. Janet Pope discuss abstract 1584 presented at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
The FOREMOST Study: Apremilast in PsA
Dr. Peter Nash reports on abstract 1691 presented at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
The SMART Study: Split Dose Oral Methotrexate
Dr. Jack Cush discusses abstract 1583 presented at the 2023 ACR Convergence meeting in San Diego.
Watch video →
Real World Experience with PEXIVAS Low Steroid Taper
Dr. Mike Putman discusses abstract 0725 with Dr. Sophie Nagle at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Cancer and TNF inhibitors
Cancer risk minimisation is a high priority for people with rheumatic diseases, as it is for the general population. Tumor necrosis factor inhibitors (TNFi) have a long history of association with cancer risk discussions. An oral presentation by Suarez-Almazor et al provided more supportive data on using TNFi in this population.
Read more →
#ACRbest Abstracts – Day 2
Our reporters have been prolific in finding the hot abstracts, those that were most attended or those that are getting the most buzz on social media. Here are RheumNow's #ACRbest abstract reports from Monday, November 13, 2023 at #ACR23, covering The Great Debate, SGLPT2 inhibitors in SLE, the SMART Study of MTX, TMP/SMX Prophylaxis, RA-ILD & TNF Inhibitors, cancer research and more.
Read more →
Effects of Apremilast on Cardiometabolic Effects in PsA
Dr. Peter Nash discusses abstract 1414 at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
An Interview with Kevin Winthrop: Three Questions About COVID 19
Drs. Jack Cush and Kevin Winthrop discuss COVID 19 at 2023 ACR Convergence in San Diego, CA.
Watch video →
Biologics as First-line Therapy for PMR and GCA?
Dr. Eric Dein talks with Dr. Philip Seo, one of two panelists for the Great Debate: Should PMR and GCA Be Treated with Advanced Therapies at Disease Onset? at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Dr. Antoni Chan
2 years ago
Our work showed the PSAID-12 score done remotely correlated with in-person clinic assessment of tender (r=0.58) , swollen joint count (r= 0.51), pain (r=0.84). 21% of patients had low disease activity onPSAID12 assessment, Chan A #Abst0507 #ACR23 @RheumNow https://t.co/vorth2ko39 https://t.co/Q2Y3ApD47E
Aurelie Najm
2 years ago
Why do we do translational research?
Dr Mustelin outlines different goals of basic science in #yearinreview
I would emphasize the #1: understanding pathogenesis is key to address clinical challenges
Overall “we have much more work to do than we care to admit”
@RheumNow #ACR23 https://t.co/QtBO3Go3gD
sheila
2 years ago
Year in review: Long-term outcome of pts in the MAINRITSAN trials
Better outcome in pts who received RTX every 6 months for 18 months.
Implications? May consider shorter duration of maintenance tx (<36mos)?
#ACR23 @RheumNow #vasculitis https://t.co/18cXBlfxSG
Dr. Rachel Tate
2 years ago
Great Dr. Seo presents a great quote from Prof Seza Ozen during #ACR23 YiR "What you think of as a rare manifestation of a common disease is probably a common presentation of a disease you are not aware of (yet.)" A call to arms to continue to be curious! @RheumNow https://t.co/zVcIpHZznt
Mike Putman EBRheum
2 years ago
RTX-induction subgroup, ADVOCATE
Encouraging results (remission 71% vs 56% plbo wk 52), but never forget RTX was NOT redosed at month 6, so pts randomized to prednisone had NO TREATMENT from wk 20 - wk 52
Take results w/grain of salt
@RheumNow #ACR23 #ACRBest @anisha_dua https://t.co/zVhRX3IbiL
Mike Putman EBRheum
2 years ago
Regarding monitoring of ILD: "TLC takes a lot of time and is not necessary for follow up PFTs" @sclerodermaUM
Very nice pearl; I have been including TLC in subsequent PFTs, probably not necessary
Will change my practice immediately & save patients time
@RheumNow #ACR23
The window of opportunity concept in RA shifted our focus to trying to treat disease earlier and more aggressively to improve long term outcomes. A natural development of this was to reconsider the possibility of therapeutic interventions aimed at the prevention of rheumatoid arthritis.
Of the many exciting advancements for patients with psoriatic arthritis at ACR Convergence, one upcoming therapy stood out: the dual IL-17A/F inhibitor bimekizumab. Nearly two dozen bimekizumab abstracts will be featured at this year’s meeting and it recently received authorization in Europe and the U.S. for psoriasis. That makes this the year I plan to figure out where this drug will be useful for my patients with PsA.
TheDaoIndex KDAO2011
2 years ago
The gut matters and take care of your dental health! #Yearinreview Microbiomes and RA:
1. Changing gut micro biome in mice immediately triggers inflammatory arthritis
2. Mucosal breaks allow bacteria in and trigger citrullination. #ACR23 @RheumNow https://t.co/Iini9yE8dJ
Md Yuzaiful Md Yusof
2 years ago
#ACR23 Year in Review. Dr Seo did a great job in highlighting key papers.
#SLE #Tyk2 Phase 2 RCT of Deucravacitinib recruited pts of diverse ancestry. More pts on DEUC met SRI-4 response vs PBO. Question remains about the inverse/flat dose response. Going to Phase 3 @RheumNow https://t.co/68rYjEnWyN
Aurelie Najm
2 years ago
More studies emphasizing the role of microbiome in RA
1- Directly arthritogenic microbe strain confirmed in mice model
2- Gingivitis and oral microbiome can trigger citrullination and ACPA production
Dr Tomas Mustelin #yearinreview
@RheumNow #ACR23 https://t.co/uBd1UEgLRz
sheila
2 years ago
Vitamin D and bone health 🦴
Dr. Connie Weaver discusses the effect of Vit D on bone as well as dietary recomms fr diff groups.
Are your pts at risk of Vit d deficiency?👇
#ACR23 @RheumNow @rheumarhyme https://t.co/XcopyBHAoj
Meral K. El Ramahi, MD MeralElRamahiMD
2 years ago
Delighted to be joining my colleagues below to reporting on #ACR23 for @Rheumnow.
Tune-in for coverage and follow my colleagues below as well! https://t.co/rdLZbPGj3O https://t.co/hhwYf4YyLv
In clinical practice, pulmonary manifestations of rheumatic medical diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and peripheral spondyloarthritis (pSpA) are typically not screened for upon diagnosis of a rheumatic disease in patients without any signs or symptoms suggestive of pulmonary involvement.
For over 70 years, glucocorticoids, (GC) have been a part of standard therapy in SLE. They are classically used to not only induce remission or treat an acute flare, but also as maintenance therapy. They are a valuable 'friend' if used wisely, and can become a 'foe' if used excessively.
Poster Hall